Combined Semi-mechanistic Target-Mediated Drug Disposition and Pharmacokinetic–Pharmacodynamic Models of Alirocumab, PCSK9, and Low-Density Lipoprotein Cholesterol in a Pooled Analysis of Randomized Phase I/II/III Studies

BACKGROUND AND OBJECTIVES: Alirocumab is a cholesterol-lowering monoclonal antibody targeting proprotein convertase subtilisin kexin type 9 (PCSK9) indicated in the prevention of cardiovascular risk and exhibiting target-mediated drug disposition (TMDD). The aim of this work was to develop an integr...

Descripción completa

Detalles Bibliográficos
Autores principales: Nolain, Patrick, Djebli, Nassim, Brunet, Aurélie, Fabre, David, Khier, Sonia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633469/
https://www.ncbi.nlm.nih.gov/pubmed/35974290
http://dx.doi.org/10.1007/s13318-022-00787-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633469/
https://www.ncbi.nlm.nih.gov/pubmed/35974290
http://dx.doi.org/10.1007/s13318-022-00787-4

Ejemplares similares